Jessica Haug

533 total citations
23 papers, 423 citations indexed

About

Jessica Haug is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jessica Haug has authored 23 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 13 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Jessica Haug's work include Multiple Myeloma Research and Treatments (20 papers), Protein Degradation and Inhibitors (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Jessica Haug is often cited by papers focused on Multiple Myeloma Research and Treatments (20 papers), Protein Degradation and Inhibitors (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Jessica Haug collaborates with scholars based in United States, Czechia and China. Jessica Haug's co-authors include S. Vincent Rajkumar, Shaji Kumar, Teresa K. Kimlinger, Michael Timm, Linda Wellik, Philip R. Greipp, Vijay Ramakrishnan, Thomas E. Witzig, John A. Lust and Michael Kline and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Jessica Haug

21 papers receiving 418 citations

Peers

Countries citing papers authored by Jessica Haug

Since Specialization

Citations

This map shows the geographic impact of Jessica Haug's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica Haug with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica Haug more than expected).

Fields of papers citing papers by Jessica Haug

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica Haug. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica Haug. The network helps show where Jessica Haug may publish in the future.

Co-authorship network of co-authors of Jessica Haug

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica Haug. A scholar is included among the top collaborators of Jessica Haug based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica Haug. Jessica Haug is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma 2019 ·Haematologica ·Vijay Ramakrishnan, Kevin C. Miller, (unknown), Teresa K. Kimlinger, Jessica Haug, Sanjay Kumar, Wilson I. Gonsalves, S. Vincent Rajkumar, Shaji Kumar	27
2	Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma 2016 ·Oncotarget ·Vijay Ramakrishnan, Marcus V. Gomez, Vivek Prasad, Teresa K. Kimlinger, (unknown), (unknown), Jessica Haug, Lintao Bi, S. Vincent Rajkumar, Shaji Kumar	20
3	Abstract 2653: Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma 2015 ·Cancer Research ·Jeremy T. Larsen, Vijay Ramakrishnan, Jessica Haug, Teresa K. Kimlinger, Somdutta Sen, Dinesh Mahajan, Sundeep Dugar, S. Vincent Rajkumar, Shaji Kumar	2
4	Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001 2014 ·Leukemia Research ·Vijay Ramakrishnan, Teresa K. Kimlinger, Michael Timm, Jessica Haug, S. Vincent Rajkumar, Shaji Kumar	13
5	Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway 2012 ·PLoS ONE ·Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug, (unknown), Linda Wellik, (unknown), S. Vincent Rajkumar, Shaji Kumar	52
6	Abstract 5669: Mechanisms of activity and drug resistance with proteasome inhibitors in multiple myeloma: Comparison of bortezomib and the investigational drug MLN9708 2012 ·Cancer Research ·Giada Bianchi, Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug, S. Vincent Rajkumar, Shaji Kumar	3
7	Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin 2011 ·American Journal of Hematology ·Vijay Ramakrishnan, Michael Timm, Jessica Haug, Teresa K. Kimlinger, (unknown), Linda Wellik, Thomas E. Witzig, S. Vincent Rajkumar, Alex A. Adjei, Shaji Kumar	29
8	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone 2011 ·Blood ·Shaji Kumar, Hajime Uno, Susanna Jacobus, Scott A. Van Wier, Greg Ahmann, Kimberly J. Henderson, Natalie S. Callander, Jessica Haug, David S. Siegel, Philip R. Greipp, Rafaël Fonseca, S. Vincent Rajkumar	24
9	TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells 2010 ·American Journal of Hematology ·Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug, Michael Timm, Linda Wellik, (unknown), Animesh Pardanani, Ayalew Tefferi, S. Vincent Rajkumar, Shaji Kumar	49
10	Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines 2010 ·Blood ·Giada Bianchi, Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug, S. Vincent Rajkumar, Shaji Kumar	0
11	R-(-)−gossypol (AT-101) activates programmed cell death in multiple myeloma cells 2008 ·Experimental Hematology ·Michael Kline, S. Vincent Rajkumar, Michael Timm, Teresa K. Kimlinger, Jessica Haug, John A. Lust, Philip R. Greipp, Shaji Kumar	50
12	Changes in Bone Marrow Plasma Cell Surface Markers Following CD138-Magnetic Bead Based Positive Selection. 2006 ·Blood ·Teresa K. Kimlinger, S. Vincent Rajkumar, Michael Kline, Jessica Haug, Michael Timm, Thomas E. Witzig, Shaji Kumar	2
13	Phenotypic Characterization of the CD45+ and CD45− Plasma Cell Compartments in Monoclonal Gammopathies. 2006 ·Blood ·(unknown), Michael Timm, S. Vincent Rajkumar, Jessica Haug, Michael Kline, Thomas E. Witzig, Shaji Kumar	1
14	Apoptosis Rates in Myeloma Cells Can Be Significantly Affected by CD138 Sorting and by the Specific Method Used To Detect Apoptotic Cells. 2006 ·Blood ·Teresa K. Kimlinger, S. Vincent Rajkumar, Michael Kline, Michael Timm, Jessica Haug, Thomas E. Witzig, Shaji Kumar	1
15	Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vitro Activity in Multiple Myeloma. 2005 ·Blood ·Shaji Kumar, Michael Timm, (unknown), Michael Kline, Jessica Haug, S. Vincent Rajkumar, Philip R. Greipp	0
16	Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination. 2005 ·Blood ·Shaji Kumar, Philip R. Greipp, Jessica Haug, Michael Kline, Wee Joo Chng, Emily Blood, Leif Bergsagel, John A. Lust, Morie A. Gertz, Rafaël Fonseca, S. Vincent Rajkumar	3
17	ABT-737, an Inhibitor of Bcl-2/Bcl-XL Proteins, Is Cytotoxic in Multiple Myeloma Cells. 2005 ·Blood ·Michael Kline, (unknown), Michael Timm, Jessica Haug, John A. Lust, S. Vincent Rajkumar, Shaji Kumar	1
18	AT-101, a Small Molecule Inhibitor of Bcl-2 Family Proteins, Has Significant In Vitro Activity in Multiple Myeloma. 2005 ·Blood ·Shaji Kumar, Michael Kline, (unknown), Michael Timm, Jessica Haug, Philip R. Greipp, Dajun Yang, S. Vincent Rajkumar	2
19	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression 2004 ·Blood ·Shaji Kumar, Thomas E. Witzig, Michael Timm, Jessica Haug, Linda Wellik, Teresa K. Kimlinger, Philip R. Greipp, S. Vincent Rajkumar	116
20	Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma 2003 ·British Journal of Haematology ·Michael A. Thompson, Thomas E. Witzig, Shaji Kumar, Michael Timm, Jessica Haug, Rafaël Fonseca, Philip R. Greipp, John A. Lust, S. Vincent Rajkumar	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact